DeNovo Sciences, a producer of liquid biopsy products, announced the appointment of Dr. Yixin Wang as Chief Scientific Officer (CSO). Dr. Wang is a veteran in molecular diagnostics where he has played significant R&D roles at large, multi-national companies including Parke-Davis/Pfizer, Veridex/Johnson & Johnson and Ventana/Roche. He will lead strategic initiatives for clinical development of DeNovo’s technology in the U.S. and overseas. Yixin brings extensive and critical expertise from his experience on development of several cancer diagnostic technologies, especially the first and only FDA approved circulating tumor cell (CTC) technology, CellSearch from Veridex.
“I am excited to have Dr. Wang join our DeNovo team. This marks a great validation for our technology. With Yixin’s specific experience on development and commercialization of CellSearch and CTC technologies, DeNovo can now put a confident foot forward as it embarks on its own FDA trial,” said Dr. Kalyan Handique, CEO of DeNovo Sciences.
Dr. Wang has held several R&D leadership positions prior to joining DeNovo Sciences, including vice president of molecular probes at Ventana Medical Systems/Roche and executive director of R&D at Veridex. Yixin also has extensive experience working with pharmaceutical groups, identified molecular markers and developed and validated companion molecular assays. Yixin earned his Ph.D. in Molecular Biology from Cornell University and his B.S. in Biochemistry from Beijing University.
“During my tenure at Ventana/Roche, I collaborated with the DeNovo team on validation of its CTC technology,” said Wang. “I strongly believe that the platform has a clear competitive advantage and a great potential to be applied in clinical diagnostics both in US and worldwide. It would enable molecular diagnostic tests on CTCs for many cancer types and pathways in order to deliver clinically relevant information to our customers. I look forward to working with the DeNovo team to take the technology to its fruition.”